NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Older patients actually did better on DCVax-L, not worse, than the same patients in the ECA.

According to the JAMA paper, DCVax-L showed improved survival compared to controls across subgroups including older age, significant residual disease, and recurrence. The largest relative improvement was seen in patients aged =65 years (HR 0.63 for DCVax-L vs. controls) and those with significant residual disease after resection (HR 0.65).

Although the absolute survival was greater in patients with positive prognostic factors, the relative survival benefit of DCVax-L vs ECPs was larger in certain patients who generally fare worse with SOC, including older patients, patients with substantial residual tumor, and patients with recurrent disease. These encouraging results suggest that cancer vaccines could be relevant for a broad range of clinical settings.

The median (range) age was 56 (19-73) years...

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847


For the overall 331 patients enrolled (including both the DCVax-L treated group and placebo group), the median age was 56 years, with a range of 19-73 years old.

61% of the total 331 patients were men.

In the survival subgroup analyses, 50 patients in the DCVax-L group and 45 patients in the ECA were aged =65 years.

Both the DCVax-L and control groups included a subgroup of around 15-20% over age 65.

Per the Stupp Trial:

RESULTS
A total of 573 patients from 85 centers underwent randomization. The median age was 56 years...

https://www.nejm.org/doi/full/10.1056/nejmoa043330